litlas
Log inCreate account

Pamela Salman

Active 2010–2024

28
Papers
20,585
Citations
26
h-index
28
i10-index

Citations

Citations per year for Pamela Salman2001: 2 citations2004: 1 citations2006: 1 citations2008: 1 citations2010: 13 citations2011: 36 citations2012: 45 citations2013: 48 citations2014: 71 citations2015: 50 citations2016: 57 citations2017: 63 citations2018: 171 citations2019: 889 citations2020: 1,057 citations2021: 1,050 citations2022: 996 citations2023: 819 citations2024: 1,308 citations2025: 628 citations2026: 14 citations2002–2003: no citations, so these years are not shown2005: no citations, so this year is not shown2007: no citations, so this year is not shown2009: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,445 citing papers, 20.6% of this breakdownChina: 1,706 citing papers, 14.4% of this breakdownItaly: 737 citing papers, 6.2% of this breakdownJapan: 661 citing papers, 5.6% of this breakdownUnited Kingdom: 623 citing papers, 5.3% of this breakdownFrance: 610 citing papers, 5.2% of this breakdownGermany: 501 citing papers, 4.2% of this breakdownSpain: 465 citing papers, 3.9% of this breakdownCanada: 372 citing papers, 3.1% of this breakdownSouth Korea: 357 citing papers, 3% of this breakdownAustralia: 278 citing papers, 2.4% of this breakdownNetherlands: 254 citing papers, 2.1% of this breakdown
0%20.6%Other 24%

Institutions

Fields

  • Medicine82.8%
  • Biochemistry, Genetics and Molecular Biology10.8%
  • Immunology and Microbiology4.2%
  • Neuroscience0.6%
  • Engineering0.4%
  • Computer Science0.3%
  • Other0.9%

Topics

  • Cancer Immunotherapy and Biomarkers18.6%
  • Renal cell carcinoma treatment6.5%
  • Lung Cancer Treatments and Mutations4.4%
  • Gastric Cancer Management and Outcomes3.9%
  • Immunotherapy and Immune Responses3.6%
  • Cancer Genomics and Diagnostics3.5%
  • Other59.5%

Coauthors

All papers

Open in search
  1. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

    Authors: Yelena Y. Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli, Tianshu Liu, Michael Schenker, Patricio Yañez, Mustapha Tehfé, Rubén Dario Kowalyszyn, Michalis V. Karamouzis, Ricardo Brugés, Thomas Zander, Roberto Pazo-Cid, Erika Hitre, Kynan Feeney, James M. Cleary, Valerie Poulart, Dana Cullen, Ming Lei, Hong Xiao, Kaoru Kondo, Mingshun Li, Jaffer A. Ajani - The Lancet 2021 cited by 2,927

  2. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Authors: Robert J. Motzer, Nizar M. Tannir, Ray McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Toni K. Choueiri, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Victoria Neiman, Christian Kollmannsberger, Pamela Salman, Howard Gurney, Robert D. Hawkins, Alain Ravaud, Marc‐Oliver Grimm, Sergio Bracarda, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Allen C. Chen, Sabeen Mekan, M. Brent McHenry, Megan Wind‐Rotolo, Justin Doan, Padmanee Sharma, Hans J. Hammers, Bernard Escudier - New England Journal of Medicine 2018 cited by 4,643

  3. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

    Authors: Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Manuel Cobo, Michael Schenker, Bogdan Żurawski, J. Menezes, Eduardo Richardet, Jaafar Bennouna, Enriqueta Felip, Óscar Juan, Aurelia Alexandru, Hiroshi Sakai, Alejo Lingua, Pamela Salman, Pierre-Jean Souquet, Pedro De Marchi, Claudio Martín, M. Pérol, Arnaud Scherpereel, Shun Lü, Thomas John, David P. Carbone, S. Meadows–Shropshire, Shruti Agrawal, Abderrahim Oukessou, Jinchun Yan, Martin Reck - The Lancet Oncology 2021 cited by 1,362

  4. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

    Authors: Nicoletta Colombo, Coraline Dubot, Domenica Lorusso, M. Valeria Cáceres, Kosei Hasegawa, Ronnie Shapira‐Frommer, Krishnansu S. Tewari, Pamela Salman, Edwin Hoyos Usta, Eduardo Yañez, Mahmut Gümüş, Mivael Olivera Hurtado de Mendoza, Vanessa Samouëlian, Vincent Castonguay, Arkhipov Alexander, Sarper Toker, Kan Li, Stephen J. O’Keefe, Bradley J. Monk - New England Journal of Medicine 2021 cited by 992

  5. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

    Authors: Sun Young Rha, Do‐Youn Oh, Patricio Yañez, Yuxian Bai, Min‐Hee Ryu, Jeeyun Lee, Fernando Rivera, Gustavo Vasconcelos Alves, Marcelo Garrido, Kai‐Keen Shiu, M. Fernández, Jin Li, Maeve A. Lowery, Timuçin Çil, Felipe Melo Cruz, Shukui Qin, Suxia Luo, Hongming Pan, Zev A. Wainberg, Lina Yin, Sonal Bordia, Pooja Bhagia, Lucjan Wyrwicz, Guillermo Méndez, Juan Manuel O’Connor, Alvaro Yanzi Castilla, Juan Cundom, Diego Kaen, Rachel Wong, Weng Ng, Morteza Aghmesheh, Mauricio Peressoni, Carlos Eduardo Mattos da Cunha Andrade, Fábio Franke, Gustavo R. Alves, Felipe Jose Cruz, Karina Vianna, Maria Marcela Monteiro, Michael J. Raphael, Scott Berry, Raymond Woo-Jun Jang, Ann Tan, Jamil Asselah, Patricio Yañez Weber, Mauricio Mahave, César Sánchez, Pamela Salman, Yuxian Bai, Jin Li, Xiaochun Zhang, Tianshu Liu, Xiaoyan Lin, Shukui Qin, Jianwei Yang, Suxia Luo, Wěi Li, Jieer Ying, Xi Chen, Shan Zeng, Yanli Qu, Lin Yang, Lin Zhao, Ping Chen, Hongming Pan, Enxiao Li, Feng Ye, Jianwei Lu, Xinjun Liang, Qun Zhao, Xianli Yin, Junhe Li, Junhe Li, Guoqing Lv, Shouguo Li, Álvaro Guerrero, Juan Rubiano, M. Fernández, Ray Manneh Kopp, Adrián Guzmán Ramírez, Luis Corrales, Ileana Gonzalez Herrera, Bohuslav Melichar, Tomáš Büchler, Tomáš Svoboda, Radka Obermannová, David Vrána, Jakub Cvek, Per Pfeiffer, Lene Bæksgaard, Mette Yilmaz, Valérie Boige, Daniel López‐Trabada, Christophe Borg, Diane Pannier, Sandrine Hiret, Frédéric Di Fiore, Jean‐Philippe Metges, Dirk Arnold, Uwe M. Martens, Florian Lordick and 128 more - The Lancet Oncology 2023 cited by 622

  6. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

    Authors: Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański, Jong Seok Lee, Gregory A. Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak A. Burgers, Pamela Salman, Hossein Borghaei, Suresh S. Ramalingam, Julie R. Brahmer, Martin Reck, Kenneth J. O’Byrne, William J. Geese, George Green, Chang Han, Joseph D. Szustakowski, Prabhu Bhagavatheeswaran, Diane Healey, Yali Fu, Faith E. Nathan, Luis Paz‐Ares - New England Journal of Medicine 2018 cited by 3,137

  7. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826

    Authors: Bradley J. Monk, Nicoletta Colombo, Krishnansu S. Tewari, Coraline Dubot, M. Valeria Cáceres, Kosei Hasegawa, Ronnie Shapira‐Frommer, Pamela Salman, Eduardo Yañez, Mahmut Gümüş, Mivael Olivera, Vanessa Samouëlian, Vincent Castonguay, А. В. Архипов, Cumhur Tekin, Kan Li, Stephen J. O’Keefe, Domenica Lorusso, on behalf of the KEYNOTE-826 Investigators - Journal of Clinical Oncology 2023 cited by 236

  8. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

    Authors: Robert J. Motzer, Brian I. Rini, David F. McDermott, Osvaldo Arén Frontera, Hans J. Hammers, Michael A. Carducci, Pamela Salman, Bernard Escudier, Benoit Beuselinck, Asim Amin, Camillo Porta, Saby George, Victoria Neiman, Sergio Bracarda, Scott S. Tykodi, Philippe Barthélémy, Raya Leibowitz‐Amit, Elizabeth R. Plimack, Sjoukje F. Oosting, Bruce G. Redman, Bohuslav Melichar, Thomas Powles, Paul Nathan, Stéphane Oudard, David Pook, Toni K. Choueiri, Frede Donskov, Marc‐Oliver Grimm, Howard Gurney, Daniel Y.C. Heng, Christian Kollmannsberger, Michael R. Harrison, Yoshihiko Tomita, Ignacio Durán, Viktor Grünwald, M. Brent McHenry, Sabeen Mekan, Nizar M. Tannir - The Lancet Oncology 2019 cited by 780

  9. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma

    Authors: Georgina V. Long, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Pamela Salman, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, J. Menezes, Stéphane Dalle, Ana Arance, Jean‐Jacques Grob, Sarah Keidel, Anadil Shaikh, Anne Marie Sobiesk, Sonia Dolfi, Hussein A. Tawbi - NEJM Evidence 2023 cited by 124

  10. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial

    Authors: J. Randolph Hecht, Yung‐Jue Bang, Shukui Qin, Hyun Cheol Chung, Jianming Xu, Joon Oh Park, Krzysztof Jeziorski, Yaroslav Shparyk, Paulo M. Hoff, Alberto Sobrero, Pamela Salman, Jin Li, Светлана Проценко, Zev A. Wainberg, Marc Buyse, Karen Afenjar, Vincent Houé, Agathe Garcia, Tomomi Kaneko, Yingjie Huang, S. Khan‐Wasti, Sergio Santillana, Michael F. Press, Dennis J. Slamon - Journal of Clinical Oncology 2015 cited by 621

  11. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

    Authors: Cora N. Sternberg, Ian D. Davis, Jozef Mardiak, Cezary Szczylik, Eunsik Lee, John Wagstaff, Carlos H. Barrios, Pamela Salman, Oleg Gladkov, Alexander Kavina, Juan J. Zarbá, Mei Chen, Lauren McCann, Lini Pandite, Debasish Roychowdhury, Robert E. Hawkins - Journal of Clinical Oncology 2010 cited by 2,483

  12. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

    Authors: Florian Lordick, Yoon‐Koo Kang, Hyun Cheol Chung, Pamela Salman, Sang Cheul Oh, G. Bodoky, G. Kurteva, Constantin Volovăț, Vladimir Moiseyenko, В. А. Горбунова, Joon Oh Park, Akira Sawaki, Ilhan Celik, Heiko Götte, Helena Melezínková, Markus Moehler - The Lancet Oncology 2013 cited by 838

  13. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

    Authors: Robert J. Motzer, Bernard Escudier, David F. McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Thomas Powles, Frede Donskov, Elizabeth R. Plimack, Philippe Barthélémy, Hans J. Hammers, Saby George, Viktor Grünwald, Camillo Porta, Victoria Neiman, Alain Ravaud, Toni K. Choueiri, Brian I. Rini, Pamela Salman, Christian Kollmannsberger, Scott S. Tykodi, Marc‐Oliver Grimm, Howard Gurney, Raya Leibowitz‐Amit, Poul Geertsen, Asim Amin, Yoshihiko Tomita, M. Brent McHenry, Shruti Shally Saggi, Nizar M. Tannir - Journal for ImmunoTherapy of Cancer 2020 cited by 225

  14. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Bradley J. Monk, Krishnansu S. Tewari, Coraline Dubot, M. Valeria Cáceres, Kosei Hasegawa, Ronnie Shapira‐Frommer, Pamela Salman, Eduardo Yañez, Mahmut Gümüş, Mivael Olivera Hurtado de Mendoza, Vanessa Samouëlian, Vincent Castonguay, Arkhipov Alexander, Cumhur Tekin, Kan Li, Allison Martin Nguyen, Matthew Monberg, Nicoletta Colombo, Domenica Lorusso - The Lancet Oncology 2023 cited by 70

  15. Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

    Authors: Krishnansu S. Tewari, Nicoletta Colombo, Bradley J. Monk, Coraline Dubot, M. Valeria Cáceres, Kosei Hasegawa, Ronnie Shapira‐Frommer, Pamela Salman, Eduardo Yáñez, Mahmut Gümüş, Mivael Olivera Hurtado de Mendoza, Vanessa Samouëlian, Vincent Castonguay, Alexander Arkhipov, Cumhur Tekin, Kan Li, Sarper Toker, Stephen J. O’Keefe, Domenica Lorusso - JAMA Oncology 2023 cited by 59

  16. Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2–Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial

    Authors: Amir Sonnenblick, Dominique Agbor‐Tarh, Ian Bradbury, Serena Di Cosimo, Hatem A. Azim, Debora Fumagalli, Séverine Sarp, Antonio C. Wolff, Michael Andersson, Judith R. Kroep, Tanja Čufer, Sérgio D. Simon, Pamela Salman, Masakazu Toi, Lyndsay N. Harris, Julie R. Gralow, Maccon Keane, Alvaro Moreno‐Aspitia, Martine Piccart, Evandro de Azambuja - Journal of Clinical Oncology 2017 cited by 167

  17. Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

    Authors: Fred Saad, Egils Vjaters, Neal D. Shore, David Olmos, Nianzeng Xing, Andrea Juliana Gomes, Augusto César de Andrade Mota, Pamela Salman, Mindaugas Jievaltas, Albertas Ulys, M. Jakubovskis, Evgeny Kopyltsov, Weiqing Han, Liina Nevalaita, Isabella Testa, Marie‐Aude Le Berre, Iris Kuss, Kunhi Parambath Haresh, Vinod Ganju, Howard Gurney, Laurence E. Krieger, Vineet Kwatra, Sanjeev Sewak, Amanda Gwendolyn Stevanovic, Andrew Weickhardt, Alan A. Azambuja, Flavio Mavignier Cárcano, Mateus Gonçalves Costa, Felipe José Silva Melo Cruz, Juliana de Menezes, Charles Andreé Joseph de Pádua, Adriano Augusto Peclat de Paula, Carlos Eugênio Escovar, Fabio Leite Couto Fernandez, O. Gampel, Andrea Juliana Gomes, Murilo Luz, Gisele Marinho dos Santos, Augusto César de Andrade Mota, Lucas Nogueira, Daniel D’Almeida Preto, Alexandre C. Sant'Anna, Katsuki Arima Tiscoski, Jonathan Giddens, G. Kenneth Jansz, Julian Kim, Paul Quellette, Fred Saad, George Vrabec, Alejandro Acevedo Gaete, Christian Caglevic Medina, Javier Domínguez Cruzat, Marcelo Garrido Salvo, Pedro Arroyo, Anibal Salazar Huerta, Pamela Salman Boghikian, Yasna Daniela Valenzuela Velasquez, Ariel Osvaldo Zwenger, Cheng Fu, Hongqian Guo, Weiqing Han, Haowen Jiang, Junhui Jiang, Shusuan Jiang, Lie Li, Tongzu Liu, Zhenhua Liu, Lulin Ma, Jun Qi, Mingxing Qiu, Guowei Shi, Ye Tian, Ben Wan, Chun-xi Wang, Dongwen Wang, Shaogang Wang, Xiaolin Wang, Shaozhong Wei, Jitao Wu, Jun Xiao, Keji Xie, Liping Xie, Nianzeng Xing, Boxin Xue, Zejun Yan, Yongsheng Yang, Zhixian Yu, Dahong Zhang, Song Zheng, Fangjian Zhou, Suresh G. Advani, Pawan Agarwal, Niraj Bhatt, Dubashi Biswajit, Ghanashyam Biswas, Shailesh Bondarde, Chandan J. Das, SarojKumar Das Majumdar, Sujoy Gupta, Kunhi Parambath Haresh and 83 more - Journal of Clinical Oncology 2024 cited by 141

  18. Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)

    Authors: Georgina V. Long, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Pamela Salman, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, J. Menezes, Stéphane Dalle, Ana Arance, Jean‐Jacques Grob, Sarah Keidel, Anadil Shaikh, Anne Marie Sobiesk, Sonia Dolfi, Hussein A. Tawbi - Journal of Clinical Oncology 2022 cited by 47

  19. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update

    Authors: Cora N. Sternberg, Robert E. Hawkins, John Wagstaff, Pamela Salman, Jozef Mardiak, Carlos H. Barrios, Juan José Zarbá, Oleg Gladkov, Eunsik Lee, Cezary Szczylik, Lauren McCann, Stephen D. Rubin, Mei Chen, Ian D. Davis - European Journal of Cancer 2013 cited by 446

  20. LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study

    Authors: Markus Moehler, Kohei Shitara, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli, T. Liu, Michael Schenker, Patricio Yañez, Mustapha Tehfé, Valerie Poulart, Dana Cullen, Ming Lei, Kaoru Kondo, M. Li, Jaffer A. Ajani, Yelena Y. Janjigian - Annals of Oncology 2020 cited by 205

  21. First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1

    Authors: Martin Reck, Tudor–Eliade Ciuleanu, Jong Seok Lee, Michael Schenker, Clarisse Audigier-Valette, Bogdan Żurawski, Helena Linardou, Gregory A. Otterson, Pamela Salman, Makoto Nishio, Emmanuel de la Mora Jimenez, Krysztof Lesniewski-Kmak, István Albert, Samreen Ahmed, Konstantinos Syrigos, John R. Penrod, Yong Yuan, Steven I. Blum, Faith E. Nathan, Xiaowu Sun, Alejandro Moreno‐Koehler, Fiona Taylor, Kenneth J. O’Byrne - Journal of Thoracic Oncology 2021 cited by 43

  22. KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.

    Authors: Bradley J. Monk, Nicoletta Colombo, Krishnansu S. Tewari, Coraline Dubot, M. Valeria Cáceres, Kosei Hasegawa, Ronnie Shapira‐Frommer, Pamela Salman, Eduardo Yáñez, Mahmut Gümüş, Mivael Olivera Hurtado de Mendoza, Vanessa Samouëlian, Vincent Castonguay, А. В. Архипов, Cumhur Tekin, Kan Li, Stephen J. O’Keefe, Domenica Lorusso - Journal of Clinical Oncology 2023 cited by 17

  23. LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis

    Authors: Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Xiaolu Yu, Pamela Salman, Adam Płużański, Adnan Nagrial, Libor Havel, Rubén Dario Kowalyszyn, Clarisse Audigier-Valette, Yi‐Long Wu, Hossein Borghaei, Matthew D. Hellmann, Julie R. Brahmer, Martin Reck, Sundar Ramalingam, L. Zhang, Prabhu Bhagavatheeswaran, Faith E. Nathan, Kenneth J. O’Byrne - Annals of Oncology 2019 cited by 48

  24. Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study

    Authors: D. Lorusso, Nicoletta Colombo, Coraline Dubot, M.V. Cáceres, Kazuki Hasegawa, Ronnie Shapira‐Frommer, Pamela Salman, Eduardo Yáñez, Mahmut Gümüş, Mivael Olivera, Vanessa Samouëlian, Vincent Castonguay, A. Arkhipov, Ka Wan Li, S. Toker, C. Tekin, Krishnansu S. Tewari, B.J. Monk - Annals of Oncology 2024 cited by 49